Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 441, 161 (11 May 2006) | doi:10.1038/441161a; Published online 10 May 2006
Vaccines: Engineering immune evasion
John R. Mascola1
Abstract
One obstacle to realizing the promise of viral vectors for vaccine delivery is pre-existing immunity to such vectors. An adroit application of structure-based design points to a way around that problem.
There are still no vaccines against such devastating and widespread diseases as malaria, tuberculosis and AIDS. Because the traditional approach of live-attenuated vaccination is not feasible for most diseases, scientists have turned to molecularly engineered viruses that contain pathogen-specific gene inserts.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunityNature Letters to Editor (11 May 2006)
Fully Detargeted Polyethylene Glycol-coated Adenovirus Vectors Are Potent Genetic Vaccines and Escape from Pre-existing Anti-adenovirus AntibodiesMolecular Therapy Original Article
Fully Detargeted Polyethylene Glycol-coated Adenovirus Vectors Are Potent Genetic Vaccines and Escape from Pre-existing Anti-adenovirus AntibodiesMolecular Therapy Original Article
Fully Detargeted Polyethylene Glycol-coated Adenovirus Vectors Are Potent Genetic Vaccines and Escape from Pre-existing Anti-adenovirus AntibodiesMolecular Therapy Original Article
See all 9 matches for Research